A Psychedelic Tale of Two Neurotransmitters

An unexpected interaction between neurotransmitter systems may explain psychosis and hallucinations, according to a fascinating new paper.

Serotonin (5HT) and glutamate are two neurotransmitters. Up until now, it was thought that they acted independently. A given neuron might have receptors for both serotonin and glutamate, but they didn't interact: serotonin would never affect the glutamate receptors, and vice versa.

The new research overturns that view. Authors Miguel Fribourg and colleagues of Mount Sinai School of Medicine show, in a series of elegant experiments in mice, that different receptors can cluster together, forming a complex. The two receptors, serotonin's 5HT2A and glutamate's mGluR2, can talk to each other.

However, this doesn't seem to happen under normal conditions. Serotonin and glutamate don't seem to trigger the receptor interaction, or at least not very much. Only certain drugs can do it. And this is where it gets really interesting.

Psychedelic drugs, like LSD, have long been thought of as 5HT2A agonists, binding to the receptor and activating it. It turns out that this was only half right. They also inhibit mGluR2 transmission via the receptor complex. Serotonin itself is a 5HT2A agonist, but it doesn't do that. So psychedelics seem to be a kind of (for want of a better word) "superagonist".

It also works in reverse. The antipsychotic drugs clozapine and risperidone are known as 5HT2A antagonists. But Fribourg et al show that they also activate the mGluR2 receptor.

And the cross-talk can go in the other direction. Certain molecules that act on mGluR2 can either inhibit or promote 5HT2A. Unlike psychedelics and antipsychotics, these mGluR2 drugs have not been tested in humans yet. But these data predict that they will have psychedelic-like or antipsychotic-like effects, depending which way they work.

The interaction turns out to be all about G proteins, which are part of the chain of transmitter substances that convey signals within the cell, in response to neurotransmitters outside it. Here's a chart showing the effects of various drugs on the balance between different G proteins: the LSD-like psychedelic DOI has the opposite effect from the antipsychotics clozapine and risperidone.

This paper builds on a previous one from the same team showing that psychedelic 5HT2A "agonists" (like LSD and DOI) have different effects on G proteins from other, non-psychedelic agonists. That was interesting in itself but by adding glutamate to the picture, this new paper is really ground-breaking.

This goes a long way to explaining one of the mysteries of serotonin which is this:  if 5HT2A agonists like LSD are psychedelic, why aren't antidepressants the same? Almost all antidepressants work by increasing extracellular 5HT levels. That ought to mean that they activate 5HT2A receptors (indirectly). This explains why not - 5HT alone doesn't promote the crucial 5HT2A-mGluR2 interaction.

Taken together, these interesting results show clearly that 5HT2A and mGluR2 are hooking up and doing something exciting. Certainly in terms of how hallucinogens work.

I'm less convinced that this can directly explain antipsychotic effects though. The problem is that while newer "atypical" antipsychotics act on 5HT2A, the older antipsychotics don't, and atypicals are at best only slightly more effective on average.

What we don't yet know is whether this kind of complex receptor interactions can happen with other receptors. I'd have thought it unlikely that these two receptors were the only ones that could ever do it. The synapse looks like it's more complex than we could have imagined.

Fribourg M, et al. (2011). Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs. Cell, 147 (5), 1011-23 PMID: 22118459